

08-09-06

JRW

PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/735,450-180
Filing Date	December 23, 2003
First Named Inventor	NORTON
Examiner Name	Eric Olson
Art Unit	1623
Attorney Docket No.	93580.010100

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 50-1561 Deposit Account Name: Greenberg Traurig LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)

Small Entity Fee (\$)

50

25

Each independent claim over 3 (including Reissues)

200

100

Multiple dependent claims

360

180

Total Claims**Extra Claims****Fee (\$)****Fee Paid (\$)**

- 20 or HP =

x

=

Multiple Dependent Claims**Fee (\$)****Fee Paid (\$)**

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims**Extra Claims****Fee (\$)****Fee Paid (\$)**

- 3 or HP =

x

=

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets**Extra Sheets****Number of each additional 50 or fraction thereof****Fee (\$)****Fee Paid (\$)**

- 100 =

/ 50 =

(round up to a whole number) x

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Fees Paid (\$)

Other (e.g., late filing surcharge): fee under 37 C.F.R. 1.17(p)

180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 44,610	Telephone 212-801-9200
Name (Print/Type)	Richard Chern		Date August 8, 2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Larry NORTON

Serial No.: 10/735,180

Filed: December 12, 2003

For: DOSE-DENSE AND SEQUENTIAL
ADJUVANT CANCER
CHEMOTHERAPY



Group Art Unit: 1623

Examiner: Eric Olson

Attorney Docket No.: 93580.010100

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed pursuant to 37 C.F.R. 1.97(c)(2). This items listed on the PTO/SB/08B form may be considered relevant to the above captioned application.

Of further note, no representation is intended that a search has been made by applicant or that no better art references than those provided herewith are available. Moreover, the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited is, or is considered to be, material to patentability.

The Examiner is respectfully requested to consider the items listed on the attached PTO/SB/08B and to make them of record in the instant application.

This Information Disclosure Statement is being cited in accordance with 37 C.F.R. § 1.97(d). Authorization to charge the requisite fee under 37 C.F.R. 1.17(p)(\$180) from Deposit Account No. 501561, in the name of Greenberg Traurig LLP and the requisite fee transmittal is provided herewith.

In the event that there are any questions, or should additional information be required, please do not hesitate to contact Applicant's attorney at the number listed below.


08/10/2006 SSITHIB1 00000002 501561 10735180
01 FC:1806 180.00 DA


Dated: August 8, 2006

Mailing Address:
Richard Chern, Esq.
GREENBERG TRAURIG LLP
Met Life Building
200 Park Avenue, 34th Floor
New York, New York 10166
Phone: 212-801-2244
Fax: 212-801-6400

Respectfully submitted,
GREENBERG TRAURIG

By:


Richard Chern
Registration No. 44,610

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): NORTON, L.			Docket Number 93580.010100	
Serial No. 10/735,180	Filing Date December 12, 2003	Examiner Eric Olson	Group Art Unit 1623	
Invention: DOSE-DENSE AND SEQUENTIAL ADJUVANT CANCER CHEMOTHERAPY				
I hereby certify that the following correspondence:				
<div>Information Disclosure Statement (1 page); PTO SB/08b (1 pg); 4 non-patent literature documents Fee transmittal authorizing deduction of \$180.00 from Deposit Account 50-1561 Return Receipt Postcard</div>				
(Identify type of correspondence)				
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on				
August 8, 2006 (Date)		Shoba Jaglal-Grullon (Typed or Printed Name of Person Mailing Correspondence)		
		 (Signature of Person Mailing Correspondence)		
		EV 558529753 US (“Express Mail” Mailing Label Number)		
Note: Each paper must have its own certificate of mailing.				



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/735,180

Filing Date December 12, 2003

First Named Inventor NORTON

Art Unit 1623

Examiner Name Eric Olson

Attorney Docket Number 93580.010100

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		(PERLOFF, M. and NORTON L.) Surgical Adjuvant Chemotherapy of Stage II Breast Carcinoma: Two CMFVP Regimens With or Without A Subsequent Adriamycin Combination	
		(NORTON, L. and GREEN, M), The Treatment of Advanced Hodgkin's Disease With Induction Chemotherapy Followed By Late Intensification	
		(GILEWSKI, T.A, DANG, C, SURBONE A, and NORTON, L.), Cancer Medicine 5th Edition, Principles of Chemotherapy Cytokinetics, Chpt. 38	
		(NORTON, L. and SIMON R.), Tumor Growth Kinetics, Therapeutic Differentials, and Design of Treatment Schedules (An Alternate View), p.845-847	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.